

Pembrolizumab KEYNOTE-868/NRG-GY018

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



QoL data pending



#### Serious and disabling adverse effects



#### Other adjustments



Long-term plateau in the PFS curve



Pembrolizumab KEYNOTE-868/NRG-GY018

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Gynaecological Malignancies

Therapeutic Indication: Pembrolizumab with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma. (Cohort data with dMMR)

Experimental Arm: Pembrolizumab + Carboplatin and paclitaxel

Control Arm: Carboplatin, paclitaxel, and placebo



